ClinicalTrials.gg
RecruitingNCT07361510Updated Oct 23, 2026

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

A Phase 3 interventional study of Pumitamig and Pembrolizumab in Non-Small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Recruiting at 283 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 23, 202628 sites added24 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 13 under way, 3 of them phase 3. pumitamig · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
5th of 13
750 · median 594
Started
2026
with 4 others
Phase 3
2 of 13
2 open now
Primary completion
2031-10
later than 11 of 12 live
Registered
9th of 13
by date
Lead sponsor
5 of 13
Bristol-Myers Squibb

Among the 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 11 of the 12 other live ones, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About pumitamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)

Keywords

  • Non-Small Cell Lung Cancer (NSCLC)
  • 1L NSCLC
  • Programmed death ligand-1 (PD-L1)
  • Frst line NSCLC
  • Advanced NSCLC
  • Metastatic NSCLC
  • Pumitamig
  • Pembrolizumab
  • ROSETTA LUNG-202
  • ROSETTA LUNG
  • CA2660002
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with Stage IIIB/IIIC or Stage IV disease.
  • Participants must have a programmed death ligand-1 () expression ≥ 50%.
  • Participants must have as defined by (RECIST) v1.1.
  • Participants must have no prior systemic anti-tumor therapy for locally advanced or NSCLC.
  • Participants must have an (ECOG) Performance Status 0-1.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any documented actionable genomic alteration (AGA) for which (1L) approved therapies are indicated.
  • Participants must not have any symptomatic untreated central nervous system (CNS) , (carcinomatous meningitis) or spinal cord compression.
  • Participants must not have any significant cardiovascular impairment as evidenced by uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, or major thrombotic or embolic events or major hemorrhagic events (within 6 months prior to randomization), or significant risk of pulmonary hemorrhage.
  • Participants must not an active disease.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Arm A: Pumitamig

    Drug: Pumitamig

  • Active comparator
    Arm B: Pembrolizumab

    Drug: Pembrolizumab

Interventions

  • Specified dose on specified days

    Also known as: BMS-986545

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to approximately 3 years

  2. Overall survival (OS)

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. PFS by investigator according to RECIST v1.1

    Time frame: Up to approximately 3 years

  2. Objective Response (OR) by BICR according to RECIST v1.1

    Time frame: Up to approximately 3 years

  3. Duration of response (DOR) by BICR according to RECIST v1.1

    Time frame: Up to approximately 3 years

  4. Disease control rate (DCR) by BICR according to RECIST v1.1

    Time frame: Up to approximately 3 years

  5. Time to Response (TTR) by BICR according to RECIST v1.1

    Time frame: Up to approximately 3 years

  6. Time to definitive deterioration (TTDD) based on the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) defined as the time from randomization until a definitive clinically meaningful worsening in symptoms or in NSCLC-SAQ total score

    Time frame: Up to approximately 3 years

07

Study locations

180 of 283 sites recruiting
  • Southern Cancer Center Pc
    Daphne, Alabama 36526, United States
    Recruiting
    • Michael Meshad, Site 0348 · Contact111-111-1111
  • Mohtaseb Cancer Center & Blood Disorders
    Bullhead City, Arizona 86442, United States
    Recruiting
    • Hamdy Mohtaseb, Site 0424 · Contact
  • Palo Verde Hematology Oncology
    Glendale, Arizona 85304, United States
    Recruiting
    • Amol Rakkar, Site 0391 · Contact602-978-6255
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
    Recruiting
    • Afshin Gabayan, Site 0352 · Contact310-432-8955
  • Orange Coast Memorial Medical Center
    Fountain Valley, California 92708, United States
    Recruiting
    • Amol Rao, Site 0299 · Contact510673-1293
  • Cancer and Blood Specialty Clinic
    Los Alamitos, California 90720, United States
    Recruiting
    • Nihal Abdulla, Site 0027 · Contact562-706-6648
  • UCLA
    Los Angeles, California 90095, United States
    Recruiting
    • Edward Garon, Site 0422 · Contact310-926-5333
  • Pacific Cancer Care
    Monterey, California 93940, United States
    Recruiting
    • Michael Koontz, Site 0407 · Contact831-375-4105
  • Local Institution - 0403
    Oakland, California 94611, United States
    Not yet recruiting
    • Site 0403 · Contact
  • Local Institution - 0208
    Pleasant Hill, California 94523, United States
    Not yet recruiting
    • Site 0208 · Contact
  • BASS Cancer Center
    Walnut Creek, California 94598, United States
    Recruiting
    • Jewel Johl, Site 0416 · Contact916-734-3771
  • Local Institution - 0340
    Lakewood, Colorado 80401, United States
    Not yet recruiting
    • Site 0340 · Contact
  • Clermont Oncology Center
    Clermont, Florida 34711, United States
    Recruiting
    • Gopal Kunta, Site 0192 · Contact352-242-1366
  • Advanced Research
    Coral Springs, Florida 33321, United States
    Recruiting
    • Sumit Sawhney, Site 0406 · Contact954-302-3120
  • BRP- Hialeah Hospital
    Hialeah, Florida 33013, United States
    Recruiting
    • Luis Rangel, Site 0395 · Contact833-489-4968
  • Florida Clinical Trials Group
    Tamarac, Florida 33321, United States
    Recruiting
    • Chintan Gandhi, Site 0434 · Contact561-447-0614
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
    Recruiting
    • Frederick Flynt Jr, Site 0396 · Contact706-353-2990
  • Local Institution - 0412
    Augusta, Georgia 30912, United States
    Not yet recruiting
    • Site 0412 · Contact
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
    Marietta, Georgia 30060, United States
    Recruiting
    • Walid Shaib, Site 0284 · Contact770-281-5124
  • Local Institution - 0423
    Urbana, Illinois 61801, United States
    Not yet recruiting
    • Site 0423 · Contact
  • Northwest Cancer Centers, P.C.
    Dyer, Indiana 46311, United States
    Recruiting
    • Shruti Singh, Site 0409 · Contact219-924-8178
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
    Recruiting
    • Caleb Smith, Site 0350 · Contact
  • Local Institution - 0224
    Laurelton, New York 11413, United States
    Not yet recruiting
    • Site 0224 · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Mark Awad, Site 0026 · Contact617-632-3468
  • Optum Medical Care, PC
    Westbury, New York 11590, United States
    Recruiting
    • Jonathan Goldberg, Site 0214 · Contact914-242-2991
  • Novant Health Pharmacy Oncology Specialists
    Winston-Salem, North Carolina 27103, United States
    Recruiting
    • Garrett Sherwood, Site 0283 · Contact336-209-0239
  • Cincinnati Veterans Affairs Medical Center
    Cincinnati, Ohio 45220, United States
    Recruiting
    • Jaskirat Randhawa, Site 0383 · Contact
  • Local Institution - 0418
    Oklahoma City, Oklahoma 73109, United States
    Not yet recruiting
    • Site 0418 · Contact
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17602, United States
    Recruiting
    • Samuel Kerr, Site 0288 · Contact717-215-9561
  • Local Institution - 0028
    Pittsburgh, Pennsylvania 15212, United States
    Not yet recruiting
    • Site 0028 · Contact
  • WellSpan Oncology Research
    York, Pennsylvania 17403, United States
    Recruiting
    • Ikechukwu Akunyili, Site 0344 · Contact717-339-2560
  • University Of Texas Medical Branch At Galveston
    Galveston, Texas 77555, United States
    Recruiting
    • Maurice Willis, Site 0376 · Contact409-772-1164
  • Kelsey-Seybold Clinic Main Campus
    Houston, Texas 77025, United States
    Recruiting
    • Sunil Patel, Site 0353 · Contact713-442-1700
  • Texas Oncology - San Antonio
    San Antonio, Texas 78217, United States
    Recruiting
    • Krishna Alluri, Site 0351 · Contact210-656-7177
  • Local Institution - 0381
    San Antonio, Texas 78260, United States
    Not yet recruiting
    • Site 0381 · Contact
  • Local Institution - 0337
    Richmond, Virginia 23298, United States
    Not yet recruiting
    • Site 0337 · Contact
  • Shenandoah Oncology, P.C.
    Winchester, Virginia 22601, United States
    Recruiting
    • Michael McCusker Jr., Site 0349 · Contact
  • Local Institution - 0384
    Spokane, Washington 99218, United States
    Not yet recruiting
    • Site 0384 · Contact
  • Charleston Area Medical Center (CAMC)
    Charleston, West Virginia 25304, United States
    Recruiting
    • Ahmed Khalid, Site 0339 · Contact
  • HSHS St. Vincent Hospital Regional Cancer Center
    Green Bay, Wisconsin 54301, United States
    Recruiting
    • Brian Burnette, Site 0380 · Contact920-884-3135
  • Marshfield Medical Center - Marshfield
    Marshfield, Wisconsin 54449, United States
    Recruiting
    • Adedayo Onitilo, Site 0421 · Contact715-393-1454
  • Investigaciones Oncologicas C Colon SA
    Mar del Plata, Buenos Aires 7600, Argentina
    Recruiting
    • Ignacio Casarini, Site 0076 · Contact+5492235937663
  • Fundacion Estudios Clinicos
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
    • Gabriel Garbaos, Site 0229 · Contact+5493469699922
  • Sanatorio Plaza
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
    • Miriam Raimondo, Site 0362 · Contact+549341644-8821
  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L
    San Miguel de Tucumán, Tucumán Province T4000IHE, Argentina
    Recruiting
    • Elisa Maria Arroyo, Site 0420 · Contact
  • Clinica Adventista Belgrano
    Buenos Aires, 1430, Argentina
    Recruiting
    • Aldo Perfetti, Site 0058 · Contact5491132682903
  • Hospital Italiano De Cordoba
    Córdoba, X5000BAL, Argentina
    Recruiting
    • Virginia Garcia, Site 0374 · Contact+5493515054293
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
    Recruiting
    • Matthew Chan, Site 0360 · Contact+61243209890
  • Nepean Hospital
    Penrith, New South Wales 2750, Australia
    Recruiting
    • Deme Karikios, Site 0176 · Contact(02) 4734 1751
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
    Recruiting
    • Joanne Tang, Site 0154 · Contact08 7117 7265
  • Grampians Health
    Ballarat Central, Victoria 3350, Australia
    Recruiting
    • Wasek Faisal, Site 0221 · Contact61(03)53208500
  • Local Institution - 0201
    Epping, Victoria 3076, Australia
    Not yet recruiting
    • Site 0201 · Contact
  • Joondalup Health Campus
    Joondalup, Western Australia 6027, Australia
    Recruiting
    • Arman Hasani, Site 0038 · Contact+61 8 9400 9897
  • Kepler Universitaetsklinikum
    Linz, Upper Austria 4021, Austria
    Recruiting
    • David Lang, Site 0064 · Contact4373278066910
  • Landeskrankenhaus Feldkirch
    Feldkirch, 6800, Austria
    Recruiting
    • Thomas Winder, Site 0196 · Contact004355223032681
  • Universitätsklinikum St. Pölten
    Sankt Pölten, 3100, Austria
    Recruiting
    • Martin Wiesholzer, Site 0095 · Contact02742900422140
  • ZAS Augustinus
    Wilrijk, Antwerpen 2610, Belgium
    Recruiting
    • Charlotte De Bondt, Site 0188 · Contact+3232853867
  • CHIREC - site delta
    Auderghem, Bruxelles-Capitale, Région de 1160, Belgium
    Recruiting
    • Christophe Compère, Site 0333 · Contact003224348143
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Els Wauters, Site 0109 · Contact3276346826
  • Algemeen Ziekenhuis klina
    Brasschaat, 2930, Belgium
    Recruiting
    • Vincent Geldhof, Site 0345 · Contact+3234368061
  • Crio - Centro Regional Integrado de Oncologia
    Fortaleza, Ceará 60336-045, Brazil
    Recruiting
    • Eduardo Henrique Cronemberger Costa e Silva, Site 0148 · Contact+5532613111+55859884
  • Liga Norte Riograndense Contra o Câncer
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Joilda Rego, Site 0066 · Contact558440095595
  • Hospital São Lucas da PUCRS - Porto Alegre
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
    Recruiting
    • Ana Caroline Gelatti, Site 0245 · Contact(51)3320-3039
  • Fundação Pio XII - Hospital de Câncer de Barretos
    Barretos, São Paulo 14784400, Brazil
    Recruiting
    • Carlos Baston silva, Site 0085 · Contact33216600
  • A. C. Camargo Cancer Center
    São Paulo, São Paulo 01509-010, Brazil
    Recruiting
    • Helano Freitas, Site 0375 · Contact5511945544480
  • Instituto do Cancer Brasil - Taubate
    Taubaté, São Paulo 12030-200, Brazil
    Recruiting
    • Luis Eduardo Zucca, Site 0090 · Contact551733216638
  • Centro Paulista de Oncologia Clínica
    São Paulo, 01452-000, Brazil
    Recruiting
    • William Nassib William Junior, Site 0163 · Contact551135056675
  • Complex Oncology Center - Ruse EOOD
    Rousse, 7002, Bulgaria
    Recruiting
    • Nikolay Nikolaev, Site 0202 · Contact0887098616
  • "Sveta Ekaterina" Hospital
    Sofia, 1431, Bulgaria
    Recruiting
    • Galina Kurteva, Site 0326 · Contact+359887623916
  • University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna-ISUL" EAD
    Sofia, 1527, Bulgaria
    Recruiting
    • Kremena Vasileva, Site 0047 · Contact+359887123128
  • Diagnostic and Consultative Center Convex
    Sofia, 1680, Bulgaria
    Recruiting
    • Petya Balikova, Site 0325 · Contact+359 893582321
  • Bc Cancer Agency
    Prince George, British Columbia V2M7E9, Canada
    Recruiting
    • Maria Ho, Site 0411 · Contact60498831314934
  • Local Institution - 0002
    Halifax, Nova Scotia B3H 3A7, Canada
    Not yet recruiting
    • Site 0002 · Contact
  • Local Institution - 0414
    Oshawa, Ontario L1G2B9, Canada
    Not yet recruiting
    • Site 0414 · Contact
  • Local Institution - 0178
    Ottawa, Ontario K1H 8L6, Canada
    Not yet recruiting
    • Site 0178 · Contact
  • Local Institution - 0156
    Toronto, Ontario M6R 1B5, Canada
    Not yet recruiting
    • Site 0156 · Contact
  • Bradford Hill Norte
    Antofagasta, AN 1240000, Chile
    Recruiting
    • Angela Estay, Site 0361 · Contact56994198125
  • Centro de Oncología de Precisión
    Las Condes, Arica y Parinacota Region 7560908, Chile
    Recruiting
    • Pamela Salman Boghikian, Site 0302 · Contact
  • Bradfordhill
    Santiago, Santiago Metropolitan 8420383, Chile
    Recruiting
    • Carlos Rojas, Site 0199 · Contact+56998744662
  • Servicios Medicos e Investigacion Biocenter SpA
    Concepción, 4070196, Chile
    Recruiting
    • Jose Barbosa, Site 0293 · Contact
  • Instituto Nacional del Cancer
    Independencia, 8380455, Chile
    Recruiting
    • Ronald Rodriguez, Site 0150 · Contact
  • Local Institution - 0175
    Beijing, Beijing Municipality 100142, China
    Not yet recruiting
    • Site 0175 · Contact
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Yunjian Huang, Site 0167 · Contact8613805099580
  • Local Institution - 0141
    Xiamen, Fujian 361003, China
    Not yet recruiting
    • Site 0141 · Contact
  • Zhangzhou Municipal Hospital of Fujian Province
    Zhangzhou, Fujian 363000, China
    Recruiting
    • Yuanmao Huang, Site 0327 · Contact8617605966308
  • Southern Medical University Nanfang Hospital
    Guangzhou, Guangdong 510515, China
    Recruiting
    • Min Shi, Site 0312 · Contact13826259986
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515041, China
    Recruiting
    • Wen Lin, Site 0210 · Contact13612388011
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530021, China
    Recruiting
    • Shaozhang Zhou, Site 0255 · Contact8613977183708
  • Local Institution - 0317
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Site 0317 · Contact
  • Local Institution - 0046
    Zhengzhou, Henan 450008, China
    Not yet recruiting
    • Site 0046 · Contact
  • Local Institution - 0430
    Wuhan, Hubei 430079, China
    Not yet recruiting
    • Site 0430 · Contact
  • Local Institution - 0436
    Xiangyang, Hubei 441021, China
    Not yet recruiting
    • Site 0436 · Contact
  • Local Institution - 0004
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Site 0004 · Contact
  • Local Institution - 0435
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Site 0435 · Contact
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Liyun MIAO, Site 0117 · Contact13813920964
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Guoren Zhou, Site 0316 · Contact8613951682839
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Anwen Liu, Site 0023 · Contact8613767120022
  • Local Institution - 0177
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Site 0177 · Contact
  • Local Institution - 0014
    Xi'an, Shaanxi 710038, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0429
    Jinan, Shandong 250013, China
    Not yet recruiting
    • Site 0429 · Contact

Showing the first 100 of 283 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2031, 67 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 67 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 23, 2026
StartActual
Mar 12, 2026
Primary completionEst.
Oct 14, 2031
CompletionEst.
Oct 14, 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
28 sites added, 24 sites removed
Show 28 added (5 China, 4 France, 4 United States, 3 Germany, 2 Mexico, 2 Japan, 1 Belgium, 1 Bulgaria, 1 Canada, 1 Chile, 1 Italy, 1 Argentina, 1 Hungary, 1 Spain)
  • CHIREC - site delta · Auderghem, Belgium
  • University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna-ISUL" EAD · Sofia, Bulgaria
  • Bc Cancer Agency · Prince George, Canada
  • Instituto Nacional del Cancer · Independencia, Chile
  • Local Institution - 0436 · Xiangyang, China
  • Jiangsu Cancer Hospital · Nanjing, China
  • Fudan University-Zhongshan Hospital · Shanghai Shi, China
  • Local Institution - 0447 · Montpellier, France
  • Local Institution - 0445 · Villefranche-sur-Saône, France
  • Groupe hospitalier Paris saint Joseph · Paris, France
  • Westpfalz- Klinikum · Kaiserslautern, Germany
  • Helios Klinikum Emil Von Behring Gmbh · Berlin, Germany
  • Staedtisches Klinikum Braunschweig gGmbH · Braunschweig, Germany
  • IRCCS AOM Azienda Ospedaliera Metropolitana · Genova, Italy
  • Local Institution - 0449 · Mexico City, Mexico
  • Local Institution - 0450 · Puebla City, Mexico
  • Cancer and Blood Specialty Clinic · Los Alamitos, United States
  • UCLA · Los Angeles, United States
  • Cincinnati Veterans Affairs Medical Center · Cincinnati, United States
  • Marshfield Medical Center - Marshfield · Marshfield, United States
  • Investigaciones Oncologicas C Colon SA · Mar del Plata, Argentina
  • Southern Medical University Nanfang Hospital · Guangzhou, China
  • Shanghai Chest Hospital · Shanghai, China
  • Centre Antoine-Lacassagne · Nice, France
  • Farkasgyepui Tudogyogyintezet · Farkasgyepű, Hungary
  • Ehime University Hospital · Tōon, Japan
  • Tohoku University Hospital · Sendai, Japan
  • Hospital La Princesa · Madrid, Spain
Show 24 removed
  • Local Institution - 0333 · Auderghem, Belgium
  • Local Institution - 0047 · Sofia, Bulgaria
  • Local Institution - 0411 · Prince George, Canada
  • Local Institution - 0150 · Independencia, Chile
  • Local Institution - 0316 · Nanjing, China
  • Local Institution - 0212 · Shanghai Shi, China
  • Local Institution - 0207 · Paris, France
  • Local Institution - 0357 · Kaiserslautern, Germany
  • Local Institution - 0231 · Berlin, Germany
  • Local Institution - 0158 · Braunschweig, Germany
  • Local Institution - 0111 · Genova, Italy
  • Local Institution - 0027 · Los Alamitos, United States
  • Local Institution - 0422 · Los Angeles, United States
  • Local Institution - 0383 · Cincinnati, United States
  • Local Institution - 0421 · Marshfield, United States
  • Local Institution - 0076 · Mar del Plata, Argentina
  • Nanfang Medical College Nanfang Hospital · Guangzhou, China
  • Local Institution - 0122 · Shanghai Shi, China
  • Local Institution - 0398 · Nice, France
  • Local Institution - 0012 · Farkasgyepű, Hungary
  • Local Institution - 0303 · Eluru, India
  • Local Institution - 0256 · Tōon, Japan
  • Local Institution - 0257 · Sendai, Japan
  • Local Institution - 0266 · Madrid, Spain
across 2 updates, Sep 30, 2026 – Oct 23, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Saitama Medical University International Medical Center · Hidaka, JapanContact •••7189→•••4111
  • Dokkyo Medical University Saitama Medical Center · Koshigaya, JapanContact •••4122→•••1111
Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    12 sites added, 13 sites removed
    Show 12 added (4 United States, 2 China, 2 Japan, 1 Argentina, 1 France, 1 Hungary, 1 Spain)
    • Cancer and Blood Specialty Clinic · Los Alamitos, United States
    • UCLA · Los Angeles, United States
    • Cincinnati Veterans Affairs Medical Center · Cincinnati, United States
    • Marshfield Medical Center - Marshfield · Marshfield, United States
    • Investigaciones Oncologicas C Colon SA · Mar del Plata, Argentina
    • Southern Medical University Nanfang Hospital · Guangzhou, China
    • Shanghai Chest Hospital · Shanghai, China
    • Centre Antoine-Lacassagne · Nice, France
    • Farkasgyepui Tudogyogyintezet · Farkasgyepű, Hungary
    • Ehime University Hospital · Tōon, Japan
    • Tohoku University Hospital · Sendai, Japan
    • Hospital La Princesa · Madrid, Spain
    Show 13 removed
    • Local Institution - 0027 · Los Alamitos, United States
    • Local Institution - 0422 · Los Angeles, United States
    • Local Institution - 0383 · Cincinnati, United States
    • Local Institution - 0421 · Marshfield, United States
    • Local Institution - 0076 · Mar del Plata, Argentina
    • Nanfang Medical College Nanfang Hospital · Guangzhou, China
    • Local Institution - 0122 · Shanghai Shi, China
    • Local Institution - 0398 · Nice, France
    • Local Institution - 0012 · Farkasgyepű, Hungary
    • Local Institution - 0303 · Eluru, India
    • Local Institution - 0256 · Tōon, Japan
    • Local Institution - 0257 · Sendai, Japan
    • Local Institution - 0266 · Madrid, Spain
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Saitama Medical University International Medical Center · Hidaka, JapanContact •••7189→•••4111
    • Dokkyo Medical University Saitama Medical Center · Koshigaya, JapanContact •••4122→•••1111
    + 1 other change: verification date
  2. Sep 30, 2026
    16 sites added, 11 sites removed
    Show 16 added (3 China, 3 France, 3 Germany, 2 Mexico, 1 Belgium, 1 Bulgaria, 1 Canada, 1 Chile, 1 Italy)
    • CHIREC - site delta · Auderghem, Belgium
    • University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna-ISUL" EAD · Sofia, Bulgaria
    • Bc Cancer Agency · Prince George, Canada
    • Instituto Nacional del Cancer · Independencia, Chile
    • Local Institution - 0436 · Xiangyang, China
    • Jiangsu Cancer Hospital · Nanjing, China
    • Fudan University-Zhongshan Hospital · Shanghai Shi, China
    • Local Institution - 0447 · Montpellier, France
    • Local Institution - 0445 · Villefranche-sur-Saône, France
    • Groupe hospitalier Paris saint Joseph · Paris, France
    • Westpfalz- Klinikum · Kaiserslautern, Germany
    • Helios Klinikum Emil Von Behring Gmbh · Berlin, Germany
    • Staedtisches Klinikum Braunschweig gGmbH · Braunschweig, Germany
    • IRCCS AOM Azienda Ospedaliera Metropolitana · Genova, Italy
    • Local Institution - 0449 · Mexico City, Mexico
    • Local Institution - 0450 · Puebla City, Mexico
    Show 11 removed
    • Local Institution - 0333 · Auderghem, Belgium
    • Local Institution - 0047 · Sofia, Bulgaria
    • Local Institution - 0411 · Prince George, Canada
    • Local Institution - 0150 · Independencia, Chile
    • Local Institution - 0316 · Nanjing, China
    • Local Institution - 0212 · Shanghai Shi, China
    • Local Institution - 0207 · Paris, France
    • Local Institution - 0357 · Kaiserslautern, Germany
    • Local Institution - 0231 · Berlin, Germany
    • Local Institution - 0158 · Braunschweig, Germany
    • Local Institution - 0111 · Genova, Italy

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07361510
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Mar 12, 2026
Primary completion
Oct 14, 2031 (estimated)
Completion
Oct 14, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion